Table 1.

Demographics

	N (n total = 17)
Age at referral (median)	58 (IQR 54–61)
Age at cancer diagnose (median)	50 (IQR 46–55)
Women (%)	16 (94%)
Breast cancer (%)	16 (94%)
Gastric cancer (%)	1 (6%)
Baseline LVEF (mean)	63.7 ± 6.0%
Type of anti-HER2 therapy (%)
Trastuzumab only	10 (59%)
Pertuzumab + Trastuzumab	5 (29%)
TDM1	1 (6%)
Tucanitib + Trastuzumab	1 (6%)
Concomitant systemic treatment
Capecitabine	2 (12%)
Tamoxifen	2 (12%)
Denosumab	4 (24%)
Cardiovascular risk factor (%)
Hypertension	5 (29%)
Diabetes	2 (12%)
Smoker/ex-smoker	1 (6%)
Obesity	1 (6%)
Prior anthracyclines exposure (%)	8 (47%)
Prior left chest radiotherapy (%)	5 (29%)
Other previous chemotherapy
Taxanes	13 (76%)
Fluoropyridines	4 (24%)
Cyclophosphamide	1 (6%)
Mitoxantrone	1 (6%)